MPLKIP: A Potential Drug Target for Melanoma (G136647)

Target Name: MPLKIP

NCBI ID: G136647

MPLKIP

MPLKIP: A Potential Drug Target for Melanoma

MPLKIP (Melanoma-associated protein-like kinase inhibitor) is a protein that is expressed in melanoma, which is a type of skin cancer. The MPLKIP gene has been shown to be involved in the development and progression of melanoma. Researchers are interested in using MPLKIP as a drug target or biomarker because of its potential to inhibit the growth and spread of melanoma cells.

MPLKIP is a protein that is 21 kilobytes (Kb) in length and is located on the negative strand of the DNA. It is a member of the PIK3CA gene family, which is known for its role in the development of many types of cancer. The PIK3CA gene family is thought to be involved in the regulation of cell growth, cell division, and survival.

MPLKIP is expressed in many different types of cancer, including melanoma, lung cancer, and breast cancer. It has been shown to be involved in the development and progression of these cancers by regulating the activity of many different genes. For example, MPLKIP has been shown to be involved in the regulation of the production of the protein PDGF-BB, which is a key factor in the development of cancer.

In addition to its role in the development and progression of cancer, MPLKIP is also thought to be involved in the regulation of cell survival. This is because it has been shown to play a role in the regulation of the DNA damage response, which is the process by which cells respond to damage to their DNA.

MPLKIP is also of interest as a potential drug target because of its potential to inhibit the growth and spread of melanoma cells. Studies have shown that MPLKIP inhibitors can inhibit the growth of melanoma cells in both a controlled laboratory setting and in animal models of melanoma. This suggests that MPLKIP may be an effective drug target for the treatment of melanoma.

In conclusion, MPLKIP is a protein that is expressed in many different types of cancer, including melanoma. It has been shown to be involved in the development and progression of these cancers by regulating the activity of many different genes. In addition, MPLKIP is also thought to be involved in the regulation of cell survival, which is of interest as a potential drug target. Further research is needed to fully understand the role of MPLKIP in the development and treatment of cancer.

Protein Name: M-phase Specific PLK1 Interacting Protein

Functions: May play a role in maintenance of cell cycle integrity by regulating mitosis or cytokinesis

The "MPLKIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPLKIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets